BR112022024806A2 - Compostos de espirolactama e métodos de tratamento de infecções virais com sua utilização - Google Patents

Compostos de espirolactama e métodos de tratamento de infecções virais com sua utilização

Info

Publication number
BR112022024806A2
BR112022024806A2 BR112022024806A BR112022024806A BR112022024806A2 BR 112022024806 A2 BR112022024806 A2 BR 112022024806A2 BR 112022024806 A BR112022024806 A BR 112022024806A BR 112022024806 A BR112022024806 A BR 112022024806A BR 112022024806 A2 BR112022024806 A2 BR 112022024806A2
Authority
BR
Brazil
Prior art keywords
treatment
methods
compounds
viral infections
spirolactam
Prior art date
Application number
BR112022024806A
Other languages
English (en)
Inventor
Amin Khan M
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of BR112022024806A2 publication Critical patent/BR112022024806A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65615—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing a spiro condensed ring system of the formula where at least one of the atoms X or Y is a hetero atom, e.g. S
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

COMPOSTOS DE ESPIROLACTAMA E MÉTODOS DE TRATAMENTO DE INFECÇÕES VIRAIS COM SUA UTILIZAÇÃO. São revelados compostos de espirolactama, e sais farmaceuticamente aceitáveis destes, que podem melhorar ou tratar uma infecção viral em um indivíduo necessitado. A revelação também inclui conjugados desses compostos de inibidores de protease viral com a cisteína na posição ou uma cisteína de sítio ativo equivalente na protease principal do coronavírus (Mpro).
BR112022024806A 2020-06-03 2021-06-03 Compostos de espirolactama e métodos de tratamento de infecções virais com sua utilização BR112022024806A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034076P 2020-06-03 2020-06-03
US202163133901P 2021-01-05 2021-01-05
PCT/US2021/035724 WO2021247880A2 (en) 2020-06-03 2021-06-03 Spiro-lactam compounds and methods of treating viral infections using the same

Publications (1)

Publication Number Publication Date
BR112022024806A2 true BR112022024806A2 (pt) 2023-05-02

Family

ID=76943088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024806A BR112022024806A2 (pt) 2020-06-03 2021-06-03 Compostos de espirolactama e métodos de tratamento de infecções virais com sua utilização

Country Status (11)

Country Link
US (1) US20230210851A1 (pt)
EP (1) EP4161517A2 (pt)
JP (1) JP2023528456A (pt)
KR (1) KR20230027097A (pt)
AU (1) AU2021284376A1 (pt)
BR (1) BR112022024806A2 (pt)
CA (1) CA3184348A1 (pt)
CO (1) CO2022018632A2 (pt)
IL (1) IL298343A (pt)
MX (1) MX2022015168A (pt)
WO (1) WO2021247880A2 (pt)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031539C (en) * 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Also Published As

Publication number Publication date
KR20230027097A (ko) 2023-02-27
AU2021284376A1 (en) 2023-01-05
CA3184348A1 (en) 2021-12-09
IL298343A (en) 2023-01-01
EP4161517A2 (en) 2023-04-12
MX2022015168A (es) 2023-01-16
CO2022018632A2 (es) 2022-12-30
WO2021247880A3 (en) 2022-02-03
US20230210851A1 (en) 2023-07-06
WO2021247880A2 (en) 2021-12-09
JP2023528456A (ja) 2023-07-04

Similar Documents

Publication Publication Date Title
MX2023002195A (es) Compuestos y metodos para el tratamiento de infecciones virales.
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
CY1112851T1 (el) Μεθοδος προληψης ή θεραπειας μολυνσης μ. τuβεrculosis
DOP2023000187A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BRPI0517463A (pt) inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
BR112017007545A2 (pt) derivados de carbazol
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
AR119158A1 (es) Tratamientos de angioedema hereditario
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
BRPI0514724A (pt) inibidores da enzima hiv integrase
ATE486634T1 (de) Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
BR112021025655A2 (pt) Inibidores da replicação do vírus da imunodeficiência humana
CO2022000270A2 (es) Inhibidores de enzimas
AU2022350653A1 (en) Coronavirus vaccines and methods of use
BR112022024806A2 (pt) Compostos de espirolactama e métodos de tratamento de infecções virais com sua utilização
BR112022008041A2 (pt) Compostos de pirrolidina e piperidina
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.